XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Mar. 21, 2016
Summary of Significant Accounting Policies (Details) [Line Items]            
Common stock, par value (in Dollars per share)           $ 0.001
Common stock authorized (in Shares)           360,000,000
Cash and cash equivalents (in Dollars) $ 1,323,543   $ 1,323,543   $ 5,828,548  
Restricted cash equivalents (in Dollars) 646,604   $ 646,604   $ 736,667  
Impairment of equity investments (in Dollars) 0     $ 9    
Labor pension fund percentage     6.00%      
Percentage of monthly contribution     6.00%      
Employee benefits amount (in Dollars) 3,302 $ 2,906 $ 9,948 8,268    
Employee stock-based compensation expenses (in Dollars) 0 9        
Non-employee stock-based compensation expenses (in Dollars) $ 225,740 $ 225,740 $ 5,143,483 $ 927,220    
Benefit percentage     50.00%      
Vendor One [Member]            
Summary of Significant Accounting Policies (Details) [Line Items]            
Total purchases, percentage       29.70%    
Vendor Two [Member]            
Summary of Significant Accounting Policies (Details) [Line Items]            
Total purchases, percentage       24.90%    
Vendor Three [Member]            
Summary of Significant Accounting Policies (Details) [Line Items]            
Total purchases, percentage       24.70%    
GenePharm Inc. [Member]            
Summary of Significant Accounting Policies (Details) [Line Items]            
Total accounts receivable, percentage 27.44%   27.44%      
LiveLeaf Bioscience [Member]            
Summary of Significant Accounting Policies (Details) [Line Items]            
Total accounts receivable, percentage 22.98%   22.98%      
Rgene Corporation [Member]            
Summary of Significant Accounting Policies (Details) [Line Items]            
Total revenues, percentage     79.18%      
GLIA, LLC [Member]            
Summary of Significant Accounting Policies (Details) [Line Items]            
Total revenues, percentage       39.61%    
Chartwell RX Sciences, LLC [Member]            
Summary of Significant Accounting Policies (Details) [Line Items]            
Total revenues, percentage       25.09%    
Biotech Industries [Member]            
Summary of Significant Accounting Policies (Details) [Line Items]            
Total revenue percentage 47.84%          
Agriculture Industries [Member]            
Summary of Significant Accounting Policies (Details) [Line Items]            
Total revenue percentage 16.47% 14.43%        
Pharmaceutical Industries [Member]            
Summary of Significant Accounting Policies (Details) [Line Items]            
Total revenue percentage 15.60% 47.57%        
GRAS Associates [Member]            
Summary of Significant Accounting Policies (Details) [Line Items]            
Total purchases, percentage 79.10%   40.50%      
PHARMout Labs [Member]            
Summary of Significant Accounting Policies (Details) [Line Items]            
Total purchases, percentage   89.10%        
Hanna Instruments [Member]            
Summary of Significant Accounting Policies (Details) [Line Items]            
Total purchases, percentage   10.90%